Ludger Tebartz van Elst1, Simon Maier1, Stefan Klöppel1, Erika Graf1, Carola Killius1, Marthe Rump1, Esther Sobanski1, Dieter Ebert1, Mathias Berger1, Andreas Warnke1, Swantje Matthies1, Evgeniy Perlov1, Alexandra Philipsen1. 1. From the Section for Experimental Neuropsychiatry, Clinic for Psychiatry and Psychotherapy, University Freiburg Medical Center, Hauptstr, Freiburg, Germany (Tebartz van Elst, Maier, Klöppel, Killius, Rump, Perlov); Freiburg Brain Imaging, University Freiburg Medical Center, Freiburg, Germany (Tebartz van Elst, Maier, Klöppel, Killius, Rump, Ebert, Berger); the Department of Neurology, University Freiburg Medical Center, Freiburg, Germany (Klöppel); the Clinical Trials Unit, University Freiburg Medical Center, Freiburg, Germany (Graf); the Central Institute for Mental Health, Mannheim, Germany (Sobanski); the Clinic of Psychiatry and Psychotherapy, University Freiburg Medical Center, Freiburg, Germany (Ebert, Berger, Matthies, Philipsen); the Department for Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany (Warnke); and the Department of Psychiatry and Psychotherapy, Karl Jaspers Clinic, Faculty of Medicine and Health Sciences, European Medical School, Carl von Ossietzky University Oldenburg, Oldenburg, Germany (Philipsen).
Abstract
BACKGROUND: Based on animal research several authors have warned that the application of methylphenidate, the first-line drug for the treatment of attention-deficit/hyperactivity disorder (ADHD), might have neurotoxic effects potentially harming the brain. We investigated whether methylphenidate application, over a 1-year period, results in cerebral volume decrease. METHODS: We acquired structural MRIs in a double-blind study comparing methylphenidate to placebo. Global and regional brain volumes were analyzed at baseline, after 3 months and after 12 months using diffeomorphic anatomic registration through exponentiated lie algebra. RESULTS: We included 131 adult patients with ADHD into the baseline sample, 98 into the 3-month sample (54 in the methylphenidate cohort and 44 in the placebo cohort) and 76 into the 1-year sample (37 in the methylphenidate cohort and 29 in the placebo cohort). Methylphenidate intake compared with placebo did not lead to any detectable cerebral volume loss; there was a trend toward bilateral cerebellar grey matter increase. LIMITATIONS: Detecting possible neurotoxic effects of methylphenidate might require a longer observation period. CONCLUSION: There is no evidence of grey matter volume loss after 1 year of methylphenidate treatment in adult patients with ADHD.
RCT Entities:
BACKGROUND: Based on animal research several authors have warned that the application of methylphenidate, the first-line drug for the treatment of attention-deficit/hyperactivity disorder (ADHD), might have neurotoxic effects potentially harming the brain. We investigated whether methylphenidate application, over a 1-year period, results in cerebral volume decrease. METHODS: We acquired structural MRIs in a double-blind study comparing methylphenidate to placebo. Global and regional brain volumes were analyzed at baseline, after 3 months and after 12 months using diffeomorphic anatomic registration through exponentiated lie algebra. RESULTS: We included 131 adult patients with ADHD into the baseline sample, 98 into the 3-month sample (54 in the methylphenidate cohort and 44 in the placebo cohort) and 76 into the 1-year sample (37 in the methylphenidate cohort and 29 in the placebo cohort). Methylphenidate intake compared with placebo did not lead to any detectable cerebral volume loss; there was a trend toward bilateral cerebellar grey matter increase. LIMITATIONS: Detecting possible neurotoxic effects of methylphenidate might require a longer observation period. CONCLUSION: There is no evidence of grey matter volume loss after 1 year of methylphenidate treatment in adult patients with ADHD.
Authors: Luis Guillermo Almeida Montes; Josefina Ricardo-Garcell; Lázaro Barajas De la Torre; Hugo Prado Alcántara; Reyna Beatriz Martínez García; David Avila Acosta; Antonio Fernández Bouzas Journal: J Atten Disord Date: 2011-04-13 Impact factor: 3.256
Authors: Kathryn E Gill; Peter J Pierre; James Daunais; Allyson J Bennett; Susan Martelle; H Donald Gage; James M Swanson; Michael A Nader; Linda J Porrino Journal: Neuropsychopharmacology Date: 2012-07-18 Impact factor: 7.853
Authors: Eva M Marco; Walter Adriani; Lucia A Ruocco; Rossella Canese; Adolfo G Sadile; Giovanni Laviola Journal: Neurosci Biobehav Rev Date: 2011-03-02 Impact factor: 8.989
Authors: A Marten H Onnink; Marcel P Zwiers; Martine Hoogman; Jeanette C Mostert; Cornelis C Kan; Jan Buitelaar; Barbara Franke Journal: Eur Neuropsychopharmacol Date: 2013-12-01 Impact factor: 4.600
Authors: Alexandra Philipsen; Thomas Jans; Erika Graf; Swantje Matthies; Patricia Borel; Michael Colla; Laura Gentschow; Daina Langner; Christian Jacob; Silke Groß-Lesch; Esther Sobanski; Barbara Alm; Martina Schumacher-Stien; Michael Roesler; Wolfgang Retz; Petra Retz-Junginger; Bernhard Kis; Mona Abdel-Hamid; Viola Heinrich; Michael Huss; Catherine Kornmann; Arne Bürger; Evgeniy Perlov; Gabriele Ihorst; Michael Schlander; Mathias Berger; Ludger Tebartz van Elst Journal: JAMA Psychiatry Date: 2015-12 Impact factor: 21.596
Authors: Kathrin Nickel; Ludger Tebartz van Elst; Jacek Manko; Josef Unterrainer; Reinhold Rauh; Christoph Klein; Dominique Endres; Christoph P Kaller; Irina Mader; Andreas Riedel; Monica Biscaldi; Simon Maier Journal: Front Psychiatry Date: 2018-10-23 Impact factor: 4.157
Authors: Alexandra P Lam; Swantje Matthies; Erika Graf; Michael Colla; Christian Jacob; Esther Sobanski; Barbara Alm; Michael Rösler; Wolfgang Retz; Petra Retz-Junginger; Bernhard Kis; Mona Abdel-Hamid; Helge H O Müller; Caroline Lücke; Michael Huss; Thomas Jans; Mathias Berger; Ludger Tebartz van Elst; Alexandra Philipsen Journal: JAMA Netw Open Date: 2019-05-03
Authors: Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas Journal: Front Hum Neurosci Date: 2022-09-26 Impact factor: 3.473
Authors: Dominique Endres; Ludger Tebartz van Elst; Simon J Maier; Bernd Feige; Peter Goll; Simon A Meyer; Swantje Matthies; Katharina Domschke; Thomas Lange; Esther Sobanski; Alexandra Philipsen; Kathrin Nickel; Evgeniy Perlov Journal: Biol Sex Differ Date: 2019-10-29 Impact factor: 5.027